EGFR and non-small cell lung carcinoma: In patients of advanced non-small-cell lung cancer (NSCLC) with tissue epidermal growth factor receptor (EGFR) T790M-positive, an absence of detectable plasma T790M at baseline is associated with longer progression-free survival, which may be attributed to a lower disease burden [20].